Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib

PHASE1RecruitingINTERVENTIONAL

Enrollment

Participants

Timeline

Start Date

May 7, 2025

Primary Completion Date

July 31, 2026

Study Completion Date

July 31, 2026

Conditions

HealthyHepatic Impairment

Interventions

DRUG

Mirdametinib (MEK Inhibitor)

Mirdametinib will be administered as a single, oral, 4 mg dose in the morning on Day 1 for each study participant enrolled in the study.

Trial Locations (2)

RECRUITING

Orlando Clinical Research Center, Orlando

RECRUITING

Clinical Pharmacology of Miami, Miami

All Listed Sponsors

lead

SpringWorks Therapeutics, Inc.

INDUSTRY

NCT06997276 - Effect of Hepatic Impairment on the Pharmacokinetics of Mirdametinib | Biotech Hunter | Biotech Hunter